G207 is cancer-killing viruses, so-called oncolytic viruses, for the treatment of various forms of cancer developed by MediGene AG. These viruses are specific herpes simplex viruses, or HSVs, generally known... MediGene uses these viruses, however, in a modified and "disarmed" form in order to make them utilizable as a therapeutic agent in humans.
- Mechanism
- Curator reviewed
G207, Cancer killing viruses are modified to make them utilizable as a therapeutic agent in human by switching off certain genes that normally enable the virus to multiply in healthy cells, which would destroy these cells. As a result of this genetic modification, the HSVs are able to reproduce in tumor cells solely, since only this offer an environment that compensates for the loss of the removed viral genes. Consequently, the virus is able to replicate in the tumor cells, selectively destroying them without harming healthy tissue.
- Primary indication
- Investigated for use/treatment in brain cancer.Curator reviewed
- Also known as
- G 207 · G-207 · Genetically Engineered Herpes Simplex Virus · HSV G207 · HSV-1 G207
Resolves to
What you can answer from here — as of August 08, 2026
Which drugs share a target with G207, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account